国家药监局关于修订双黄连颗粒等口服制剂处方药和非处方药说明书的公告(2020年 第40号)

2020-03-26 NMPA NMPA

  根据药品不良反应评估结果,为进一步保障公众用药安全,国家药品监督管理局决定对双黄连颗粒等口服制剂(包括颗粒剂、糖浆剂、片剂、泡腾片、分散片、咀嚼片、含片、合剂、滴丸、硬胶囊、软胶囊、滴剂)说明书【

  根据药品不良反应评估结果,为进一步保障公众用药安全,国家药品监督管理局决定对双黄连颗粒等口服制剂(包括颗粒剂、糖浆剂、片剂、泡腾片、分散片、咀嚼片、含片、合剂、滴丸、硬胶囊、软胶囊、滴剂)说明书【不良反应】、【禁忌】和【注意事项】项进行统一修订。现将有关事项公告如下:
  一、所有双黄连颗粒等口服制剂处方药和非处方药生产企业均应依据《药品注册管理办法》等有关规定,分别按照相应说明书修订要求(见附件1、2),于2020年6月30日前报省级药品监管部门备案。
  修订内容涉及药品标签的,应当一并进行修订;说明书及标签其他内容应当与原批准内容一致。在备案之日起生产的药品,不得继续使用原药品说明书。生产企业应当在补充申请备案后6个月内对已出厂的药品说明书及标签予以更换。
  二、药品生产企业应当对新增不良反应发生机制开展深入研究,采取有效措施做好药品使用和安全性问题的宣传培训,指导医师和患者合理用药。
  三、临床医师应当仔细阅读上述药品说明书的修订内容,在选择用药时,应当根据新修订说明书进行充分的效益/风险分析。
  四、患者用药前应当仔细阅读药品说明书,使用处方药的,应严格遵医嘱用药。
  五、各省级药品监管部门应当督促行政区域内上述药品的生产企业按要求做好相应说明书修订和标签、说明书更换工作,对违法违规行为依法严厉查处。
  特此公告。
  
  附件:1.双黄连颗粒等口服制剂处方药说明书修订要求
     2.双黄连颗粒等口服制剂非处方药说明书修订要求
 
  


  国家药监局
  2020年3月18日

 

 

 

国家药品监督管理局2020年第40号公告 附件1.doc

国家药品监督管理局2020年第40号公告 附件2.doc

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819211, encodeId=eede1819211aa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Mon Jul 13 05:54:38 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301708, encodeId=b5e71301e0870, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429248, encodeId=3565142924866, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507213, encodeId=6eb0150e21387, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589657, encodeId=4bd8158965e31, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819211, encodeId=eede1819211aa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Mon Jul 13 05:54:38 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301708, encodeId=b5e71301e0870, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429248, encodeId=3565142924866, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507213, encodeId=6eb0150e21387, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589657, encodeId=4bd8158965e31, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=)]
    2020-03-28 xuyu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819211, encodeId=eede1819211aa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Mon Jul 13 05:54:38 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301708, encodeId=b5e71301e0870, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429248, encodeId=3565142924866, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507213, encodeId=6eb0150e21387, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589657, encodeId=4bd8158965e31, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819211, encodeId=eede1819211aa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Mon Jul 13 05:54:38 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301708, encodeId=b5e71301e0870, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429248, encodeId=3565142924866, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507213, encodeId=6eb0150e21387, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589657, encodeId=4bd8158965e31, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1819211, encodeId=eede1819211aa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Mon Jul 13 05:54:38 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301708, encodeId=b5e71301e0870, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429248, encodeId=3565142924866, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507213, encodeId=6eb0150e21387, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589657, encodeId=4bd8158965e31, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Sat Mar 28 05:54:38 CST 2020, time=2020-03-28, status=1, ipAttribution=)]

相关资讯

12月1日起,全面实施药品上市许可持有人制度,临床试验机构备案管理,取消药品GMP、GSP认证

《中华人民共和国药品管理法》(以下称药品管理法)已由第十三届全国人大常委会第十二次会议于2019年8月26日修订通过,自2019年12月1日起施行。国家药监局正在抓紧开展配套规章、规范性文件和技术指南的制修订工作,并将按程序陆续发布。

国家药监局印发药品质量抽查检验管理办法

各省、自治区、直辖市药品监督管理局,新疆生产建设兵团药品监督管理局,中国食品药品检定研究院: 为加强药品监督管理,规范药品质量抽查检验工作,国家药监局组织修订了《药品质量抽查检验管理办法》,现印发给你们,请遵照执行。

国家药监局:取消这16项证明事项

7月24日,据国家药监局网站消息,根据《国务院办公厅关于做好证明事项清理工作的通知》(国办发〔2018〕47号)要求,为进一步减证便民、优化服务,国家药品监督管理局决定取消16项证明事项。自发布之日起,附件所列证明事项停止执行。根据《国务院办公厅关于做好证明事项清理工作的通知》(国办发〔2018〕47号)要求,为进一步减证便民、优化服务,国家药品监督管理局决定取消16项证明事项(详见附件),现予以

国家药监局谈疫苗管理法:针对疫苗特点制定,首要保障安全

国家药品监督管理局局长焦红29日表示,疫苗管理法明确地提出了疫苗应该实行最严格的监管,对疫苗的研制、生产、流通、预防接种全过程提出了特别的制度和规定,包括最严格的研制管理、进行严格的生产准入管理、严格的过程控制、严格的流通和配送管控以及做到严厉的处罚。29日,疫苗管理法专题新闻发布会举行。国家药品监督管理局局长焦红,国家药品监督管理局药品监管司司长袁林,全国人大常委会法制工作委员会行政法室主任袁杰

国家药监局:对临床急需短缺药、儿童用药等优先审批

“对临床急需的短缺药、防治重大传染病和罕见病等疾病的新药、儿童用药开设绿色通道,优先审评审批。”国家药品监督管理局政策法规司司长刘沛今天谈及新修订的药品管理法时如是说。

国家药监局批准我国首台自主知识产权碳离子治疗系统获批上市,应用于实体肿瘤治疗

2019年9月29日,国家药品监督管理局经审查,批准兰州科近泰基新技术有限责任公司的“碳离子治疗系统”医疗器械注册。